Meeting
2019 Gastrointestinal Cancers Symposium
Primary results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer.
Authors
Takaki Yoshikawa
The National Cancer Center Hospital, Tokyo, Japan
Takaki Yoshikawa , Kentaro Sakamaki , Kazuhiro Nishikawa , Kazumasa Fujitani , Kazuaki Tanabe , Yuichi Ito , Takanori Matsui , Akira Miki , Hiroshi Nemoto , Tetsu Fukunaga , Yutaka Kimura , Naoki Hirabayashi , Tsutomu Hayashi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000006378
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 93)
DOI
10.1200/JCO.2019.37.4_suppl.93
Abstract #
93
Poster Bd #
J3
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Survival benefit of conversion therapy after intensive chemotherapy for unresectable metastatic gastric cancer: A propensity score-matched analysis.
First Author: Hiroyuki Ohnuma
Poster
2016 ASCO Annual Meeting
Phase II study of chemoselection with docetaxel plus 5-fluorouracil and cisplatin induction chemotherapy and subsequent conversion surgery for locally advanced unresectable esophageal cancer.
First Author: Tomoya Yokota
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Tumor regression grade after neoadjuvant chemotherapy in patients with locally advanced gastric cancer treated with modern chemotherapy (FLOT): Experience in patients in Guatemala.
First Author: Rixci Ramirez
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama